Printer Friendly

Articles from M2 Pharma (October 22, 2018)

1-26 out of 26 article(s)
Title Author Type Words
AbbVie signs research and development collaboration with Morphic Therapeutic. 207
Amneal passes US FDA approval for marketing Carmustine for Injection USP in 100 mg/vial. 131
Amneal to unveil generic Isoproterenol Hydrochloride Injection USP in the US. 180
Anaeropharma partners with Chugai for novel oncology drugs. 213
Biohaven wins US FDA approval to proceed with the treatment of BHV-3500 in the first patient with migraine. 280
Bristol-Myers Squibb Updates on the Ongoing Regulatory Review of Opdivo Plus Low-Dose Yervoy in First-Line Lung Cancer Patients with Tumor Mutational Burden a[per mille][yen sign]10 mut/Mb. 163
Cantargia presents positive phase I trial CANFOUR clinical data with lead candidate CAN04 at ESMO 2018. 296
Daiichi Sankyo doses first patient in phase one trial assessing DS-1205 in combination with gefitinib. 209
Exelixis Releases Results from Two Analyses Evaluating Effect of PD-L1 Expression or Prior Treatment with Checkpoint Inhibitors on Efficacy of Cabozantinib in Patients with Advanced Renal Cell Carcinoma. 827
Genentech's Tecentriq in Combination with Abraxane Improves Outcomes as an Initial Treatment for People with PD-L1-Positive Metastatic Triple-Negative Breast Cancer. 159
ImmunoGen Presents Initial Data from FORWARD II Expansion Cohort Assessing Mirvetuximab Soravtansine in Combination with Keytruda. 502
Investigational Subcutaneous Formulation of Vedolizumab Achieves and Maintains Clinical Remission and Mucosal Healing at Week 52 in Patients with Moderately to Severely Active Ulcerative Colitis. 136
Kala Pharmaceuticals announces option options at an exercise price of USD9.94 per share. 196
LSK BioPharma, enters into global clinical collaboration with Jiangsu Hengrui Medicine. 216
MC3 Cardiopulmonary awarded US FDA clearance for Crescent for Veno-Venous Extracorporeal Membrane Oxygenation for acute respiratory failure. 176
Medivir presents new data from the MIV-711 phase II programme at ACR Annual Meeting on 21 October 2018. 246
Mylan commneces European commercial launch of Hulio. 153
Novaliq Touts Positive Topline Results for Its CyclASolPhase 2B/3 Essence Trial in Patients with Dry Eye Disease. 450
Novartis to acquire Endocyte. 144
Opdivo in Combination with Yervoy Shows Promising Results in Patients with Advanced form of Bladder Cancer. 698
OssDsign wins US FDA 510(k) clearance for OSSDSIGN Cranioplug for neurosurgery. 188
Pfizer Presents Overall Survival Data from PALOMA-3 Trial of Ibrance (palbociclib) in Patients with HR+, HER2- Metastatic Breast Cancer. 273
Regeneron Pharmaceuticals wins US FDA approval for Dupixent (dupilumab) as add-on maintenance therapy in asthma patients. 344
Selexis and Berkeley Lights Collaborate to Accelerate Cell Line Development with the Beacon Optofluidic Platform. 448
SeraCare introduces expanded NTRK reference material panel to detect NTRK gene fusions. 229
US Merck's Keytruda Showed a Complete Response Rate of Nearly 40% in Patients with High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Standard of Care. 837

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters